Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
← catalyst calendarSponsored by Arrowhead Pharmaceuticals (industry) · ARWR — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
446actual
Sites
196
Countries
Argentina, Australia, Belgium +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-22 | actual | When the study began enrolling |
| Primary completion | 2026-06-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Hypertriglyceridemia
Interventions
- Drug: Plozasiran Injection — also filed as ARO-APOC3
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo
measured Baseline, Month 12
Permalink · ARWR's whole pipeline · Catalyst calendar · Every registered study · What changed